Hints and tips:
Related Special Reports
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...Companies including UK’s AstraZeneca and Swiss group Roche have recently acquired or licensed weight-loss drugs in an effort to enter a market that analysts expected would exceed $100bn by 2030....
...This month, Roche agreed to buy Carmot Therapeutics, a US start-up with potential GLP-1 drugs, for up to $3.1bn....
...Western pharma groups are seeking to diversify production for the US market away from Chinese contract manufacturers, in response to draft US legislation that would prevent some Chinese companies from receiving...
...The Swiss group made SFr58.7bn ($68bn) in 2023, a 7 per cent decline from SFr63.2bn in 2022 and below analysts’ estimates....
...The group had several big disappointments in 2022. These included trial failures by its Alzheimer’s drug, gantenerumab....
...Roche’s new-ish chief executive Thomas Schinecker has admitted that drug hit rates have been low. Without some homegrown successes, the group’s shares will continue to languish....
...Roche plans to buy immunology company Telavant from Roivant and Pfizer for more than $7bn, the Swiss drugmaker said on Monday, as its new chief executive seeks to replenish the group’s medicine pipeline....
...Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing market for weight loss treatments...
...Roche will pay $7.1bn upfront and a near-term milestone payment of $150mn. Pfizer will keep the commercialisation rights outside the US and Japan....
...For some pharma groups, notably Sanofi of France, the pandemic was a time of embarrassing and very public underperformance....
...Consider how Roche spent its cash. It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...Roche has inadvertently disclosed positive results from a closely watched lung cancer drug study, sending shares in the Swiss pharma group up as much as 5 per cent....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...While the drug being developed by Swiss pharmaceutical group Roche has been tested on only one type of bacteria, the way it works suggests it could be effective against other microbes — and encourage much-needed...
...The group consists of Novo Nordisk, ASML, and LVMH (no surprises there) as well as SAP, Schneider Electric, Richemont and Ferrari....
...A former Roche manager who joined the German group last year, Anderson said he acknowledged the appeal of a “pure play structure” of pharma, crop science and over-the-counter consumer drugs....
...About 70 per cent of AMX’s sales are in Europe, to clients such as Swiss drugmaker Roche and German online food delivery group Delivery Hero. The remainder are in the US and Canada....
...Earnings: Oil major Shell, beverage maker AG Barr and air carrier Icelandair will report, as will casino operator Rank Group and biopharma companies Novozymes, Roche and Sanofi....
...Ubben disclosed a 0.83 per cent stake in Bayer a year ago, becoming a leading force behind the ousting of then chief executive Werner Baumann, who was replaced by Bill Anderson, a former Roche manager....
...Publishers, then, are having to respond to the preferences of this dedicated group of often younger readers, getting more into genres such as “romantasy”....
...Anderson, a former executive at Swiss rival Roche, said he was seeking to “rebase expectations”....
...Chief executive Bill Anderson, who joined last year after heading the pharma unit of Swiss rival Roche, said the decision “was not taken lightly” and had “considered investor input.”...
...AstraZeneca has signed a licensing agreement with Chinese company Eccogene, which is developing a weight-loss pill, while Swiss pharma group Roche bought obesity drug developer Carmot Therapeutics for $2.7bn...
...Roche recently agreed to buy the company for up to $3bn. The plan is to combine its drugs with ones in the Swiss company’s pipeline, with a view to preserving muscle mass....
International Edition